Inotiv (STU:BS50) Interest Expense : €-41.1 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Inotiv Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Inotiv's interest expense for the three months ended in Mar. 2024 was € -10.2 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was €-41.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Inotiv's Operating Income for the three months ended in Mar. 2024 was € -14.0 Mil. Inotiv's Interest Expense for the three months ended in Mar. 2024 was € -10.2 Mil. Inotiv did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Inotiv Interest Expense Historical Data

The historical data trend for Inotiv's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Interest Expense Chart

Inotiv Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Interest Expense

Get a 7-Day Free Trial

-0.58

-1.27

-1.43

-30.00

-40.31

Inotiv Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-9.82	-9.96	-10.56	-10.42	-10.20

Inotiv Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-41.1 Mil.

Inotiv (STU:BS50) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Inotiv's Interest Expense for the three months ended in Mar. 2024 was €-10.2 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-14.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was €34.5 Mil.

Inotiv's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Inotiv did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Inotiv (STU:BS50) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (STU:BS50) » Definitions » Interest Expense

Comparable Companies

STIM FONR BNR ACRS PRPH VNRX MDXH BDSX BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

NOTV:USA

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Inotiv (STU:BS50) Headlines

No Headlines